XML 17 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Cash flows from operating activities    
Net loss $ (10,735,432) $ (15,757,916)
Adjustments to reconcile net loss to cash used in operating activities    
Stock-based compensation expense 288,010 2,241,989
Depreciation, amortization and accretion 1,975,448 2,263,975
Other (gain) (1,753,568)
Issuance of restricted stocks 158,585 655,416
Impairment of intangible assets 1,856,020
Issuance of warrants 179,287
Derivative (income) (3,957,756) (212,809)
Amortization of prepaid research and development - related party (Note 9) 335,454
Loss on investment 61,519
Common stock issued to executives 509,996
Issuance of warrants to initial investors 596,434
(Gain) on sale of asset (428,374)
Warrant amendment 4,633 1,507
Changes in operating assets and liabilities:    
(Increase) in accounts receivable (204,437) (180,110)
Decrease in inventory 428,401 290,984
(Increase) in prepaid expenses and other (586,139) (126,555)
Decrease (increase) in accounts payable and other 967,641 (307,854)
(Decrease) in accrued liabilities (571,121) (146,290)
Decrease (increase) in accrued compensation 558,451 (355,359)
(Decrease) in deferred rent (5,005) (2,775)
Net cash used in operating activities (11,396,982) (10,560,768)
Cash flows used in investing activities    
Purchases of fixed assets (74,707) (53,435)
Contingent consideration payment (7,385)
Purchase payment for Natesto asset (6,000,000)
Sale of investment in Acerus 1,071,707
Sale of investment in Acerus cost (91,864)
Installment payments for Primsol asset (750,000)
Sale of Primsol asset 1,750,000
Net cash used in investing activities (82,092) (4,073,592)
Cash flows from financing activities    
Issuance of preferred, common stock and warrants 11,839,995
Issuance costs related to preferred, common stock and warrants (1,402,831)
Issuance of preferred, common stock and warrants 12,900,020
Issuance costs related to preferred, common stock and warrants (1,294,235)
Warrant exercises 640,380
Issuance of common stock to Lincoln Park Capital 631,481
Costs related to sale of common stock (24,247)
Warrant tender offer 2,243,281
Warrant tender offer cost (332,567)
Registered offering 8,602,500
Registered offering costs (997,865)
Over-allotment warrants purchased by placement agents 2,852
Net cash provided by financing activities 22,683,329 10,125,435
Net change in cash, cash equivalents and restricted cash 11,204,255 (4,508,925)
Cash, cash equivalents and restricted cash at beginning of period 877,542 8,054,190
Cash, cash equivalents and restricted cash at end of period 12,081,797 3,545,265
Non-cash transactions:    
Warrants issued to investors and underwriters (see Note 5) 4,117,997
Contingent consideration included in accounts payable 11,283
Warrant exercise of derivative warrants 40,096
Earn-out payment to Nuelle Shareholders 250,000
Fixed asset purchases included in accounts payable 58,683
Warrants issued in connection with the equity financing to the placement agents 292,630
Warrants amended in connection with warrant tender offer $ 63,183